Industry News (Therapy)

Patient Enrollment Announced in Drug Trial To Treat Non-Hodgkin's Lymphoma

Published in Cancer Weekly, January 29th, 1996

Techniclone International Corporation, Tustin, California, and Alpha Therapeutic Corporation, announced the initiation of patient enrollment in a multi-center Phase III clinical trial of Lym-1 (Oncolym) for the treatment of cancer patients with intermediate to high-grade B-cell lymphoma who are refractory to multi-drug chemotherapy.

"The patients in these studies are very sick, many with severely compromised immune systems as the result of unsuccessful chemotherapy," said Lev Verkh, Ph.D., Alpha's Associate Director of Clinical Research. "Incidence of this disease is increasing rapidly and new therapies are urgently needed, since up to 75 percent of non-Hodgkin's...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry